Pharma industry to hike prices on over 350 drugs in US
The increases are expected to come as the pharma industry prepares for the Biden Administration's Inflation Reduction Act (IRA),…
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
Bristol Myers Squibb
Claims against Dr Reddy’s over Revlimid in US dismissed
On 22nd December, 2022 and 27th December, 2022, the plaintiffs voluntarily dismissed Dr Reddy’s Laboratories Limited and Dr…
Anti-trust litigation filed against Dr Reddy’s Laboratories and other generic pharma companies in US
The complaint seeks damages for purported overpayments and equitable relief
US FDA approves Bristol Myers Squibb’s CAR-T cell therapy Breyanzi for relapsed large B-cell…
In the pivotal phase-III Transform trial, single infusion of Breyanzi significantly outperformed the nearly 30-year standard of…
Alembic Pharma receives US FDA tentative approval for Dasatinib tablets
The tentatively approved ANDA is therapeutically equivalent to the Reference Listed Drug (RLD) product Sprycel tablets, 20 mg, 50…
US FDA approves expanded use of Bristol Myers cancer drug Opdivo
The approval was based on data from a late-stage study showing the drug along with chemotherapy improved event-free survival and…
US FDA accepts Bristol Myers Squibb’s application for Orencia for priority review
If approved, Orencia would become the first therapy for the prevention of acute graft versus host disease (aGvHD)
EMA validates Bristol Myers Squibb’s two Opdivo-based applications to treat cell carcinoma
The applications are based on positive results from the phase-III CheckMate-648 trial, in which both Opdivo-based combinations…
Syngene extends research partnership with Bristol Myers Squibb until 2030
The extension envisions a 40 per cent increase in the number of scientists and the addition of a new 50,000 sq. ft. dedicated…
Bristol Myers Squibb and bluebird bio get US FDA nod for Abecma (idecabtagene vicleucel) to treat…
Abecma is a first-in-class BCMA-directed personalised immune cell therapy delivered as a one-time infusion for triple-class…